Pharmaceutical goods: waste pharmaceuticals

In 2024, pharmaceutical goods: waste pharmaceuticals trade exhibited significant decline, with global flows reaching $14,848,569 and a three-year compound annual growth rate of -24.4% (five-year: -11.4%). The all-time peak of $57,015,697 was recorded in 2006; the current level is 74% below that high-water mark.

Over the 30-year observation window (1995–2024), 55% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is decelerating (-16.3% acceleration).

The supply side is moderately concentrated (Herfindahl-Hirschman Index 0.225). The three largest exporters — Ireland ($19.3M), Panama ($9.3M), and United States ($6.3M) — collectively dominate supply flows. The leading exporter has grown at -82.2% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.134). The three largest import markets are Bulgaria ($4.3M), United States ($2.3M), and Jamaica ($1.8M). The largest importing market sources from 3 different supplying countries.

Estimated substitution elasticity: -6.75. Buyers are highly price-sensitive and can switch between suppliers relatively easily.

The dominant trade corridor is Ireland → China at $9.7M, representing 97.6% of the importer's total demand.

The volatility score for pharmaceutical goods: waste pharmaceuticals is 29 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, contracting demand signals caution before committing resources. A moderately concentrated market rewards differentiated positioning and strategic partner selection.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.